A new class of biomaterial developed by Cornell researchers for an infectious disease nanovaccine effectively boosted immunity in mice with metabolic disorders linked to gut bacteria – a population that shows resistance to traditional flu and polio vaccines. The study is the first to explore the interrelationship among nanomaterials, immune responses and the microbiome, an increasingly important area of research.
